PD-L1 blockade: Rejuvenating T cells in CLL

Blood

Volumn 126, Issue 2, 2015, Pages 126-128

  Kater, Arnon P ^a   Van Der Windt, Gerritje J W ^a  

^a ACADEMIC MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

PROGRAMMED DEATH 1 LIGAND 1; ANTIBODY; PROGRAMMED DEATH 1 RECEPTOR;

CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL AGING; CHRONIC LYMPHATIC LEUKEMIA; IMMUNOCOMPETENT CELL; NONHUMAN; NOTE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN TARGETING; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; AGING; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL TRANSFORMATION; DRUG EFFECTS; FEMALE; IMMUNE SYSTEM DISEASES; IMMUNOLOGY; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHYSIOLOGY;

AGING; ANIMALS; ANTIBODIES; ANTIGENS, CD274; CD8-POSITIVE T-LYMPHOCYTES; CELL TRANSFORMATION, NEOPLASTIC; FEMALE; IMMUNE SYSTEM DISEASES; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PROGRAMMED CELL DEATH 1 RECEPTOR;

EID: 84937780738     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2015-05-638338     Document Type: Note

References (13)

1. McClanahan F, Hanna B, Miller S, et al. PD-L1 checkpoint blockade prevents immune dysfunction and leukemia development in a mouse model of chronic lymphocytic leukemia. Blood. 2015;126(2):203-211.
2. McClanahan F, Riches JC, Miller S, et al. Mechanisms of PD-L1/PD-1-mediated CD8 T-cell dysfunction in the context of aging-related immune defects in the Em-TCL1 CLL mouse model. Blood. 2015;126(2):212-221.
3. Jain P, Keating M, Wierda W, et al. Outcomes of patients with chronic lymphocytic leukemia after discontinuing ibrutinib. Blood. 2015;125(13):2062-2067.
4. Ansell SM, Lesokhin AM, Borrello I, et al. PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma. N Engl J Med. 2015;372(4):311-319.
5. Bachy E, Coiffier B. Anti-PD1 antibody: a new approach to treatment of lymphomas. Lancet Oncol. 2014;15(1):7-8.
6. Riches JC, Davies JK, McClanahan F, et al. T cells from CLL patients exhibit features of T-cell exhaustion but retain capacity for cytokine production. Blood. 2013; 121(9):1612-1621.
7. Ramsay AG, Johnson AJ, Lee AM, et al. Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug. JClinInvest.2008;118(7):2427-2437.
8. Xerri L, Chetaille B, Serriari N, et al. Programmed death 1 is a marker of angioimmunoblastic T-cell lymphoma and B-cell small lymphocytic lymphoma/chronic lymphocytic leukemia. Hum Pathol. 2008;39(7):1050-1058.
9. Linton PJ, Dorshkind K. Age-related changes in lymphocyte development and function. Nat Immunol. 2004;5(2):133-139.
10. Gassner FJ, Zaborsky N, Catakovic K, et al. Chronic lymphocytic leukaemia induces an exhausted T cell phenotype in the TCL1 transgenic mouse model[published online ahead of print May 4, 2015. Br J Haematol.
11. Dubovsky JA, Beckwith KA, Natarajan G, et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes. Blood. 2013;122(15):2539-2549.
12. Sagiv-Barfi I, Kohrt HE, Czerwinski DK, Ng PP, Chang BY, Levy R. Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK. Proc Natl Acad Sci USA. 2015; 112(9):E966-E972.
13. Ramsay AG, Clear AJ, Fatah R, Gribben JG. Multiple inhibitory ligands induce impaired T-cell immunologic synapse function in chronic lymphocytic leukemia that can be blocked with lenalidomide: establishing a reversible immune evasion mechanism in human cancer. Blood. 2012; 120(7):1412-1421.